Skip to main content

GNS, Bristol-Myers Squibb Building Computer Models for Immuno-inflammation Research

NEW YORK (GenomeWeb News) – GNS Healthcare today announced a deal to use clinical and molecular information from Bristol-Myers Squibb aimed at immuno-inflammation.

The goal of the collaboration is to discover new biomarkers and uncover new disease biology.

GNS will use its reverse-engineering and forward-simulation, or REFS, platform and data from Bristol-Myers Squibb to build computer models, "in a hypothesis-free, unbiased manner that will be simulated to identify key molecular mechanisms," the Cambridge, Mass.-based company said.

The computer models will serve to support virtual clinical trials that simulate the clinical effect of inhibiting various drug targets and to help identify new molecular targets for specific types of patients.

Data from the drug manufacturer will include genetic information, gene expression levels, specific blood markers, and clinical outcomes.

"This is the first step in building a significantly advanced in silico research paradigm that may enable development of new therapies based directly on human data, and address the needs of patients with particular genetics and molecular phenotypes, ultimately enabling the optimization of individualized patient outcomes," Iya Khalil, executive vice president and co-founder of GNS, said in a statement.

Financial and other terms of the collaboration were not disclosed.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.